

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Foster
Date of last notice	17 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Mr Terry Foster + Ms Vickey S Foster - beneficiary Citicorp Nominees Pty Limited – beneficiary Citicorp Nominees Pty Limited – beneficiary
Date of change	i) 5 March 2025 ii) 12 February 2025
No. of securities held prior to change	
David Foster	5,646,829 fully paid ordinary shares 500,000 listed options exercisable at \$0.06 expiring 14 March 2025 4,000,000 options exercisable at \$0.15 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months)
Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	105,740 fully paid ordinary shares 20,588 listed options exercisable at \$0.06 expiring 14 March 2025
Citicorp Nominees Pty Limited	71,303 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Fully paid ordinary shares
Number acquired	i) 500,000 ii) 20,588
Number disposed	
David Foster	i) 500,000 listed options exercised at \$0.06 expiring 14 March 2025
Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	ii) 20,588 listed options exercisable at \$0.06 expiring 14 March 2025
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	i) \$30,000.00 ii) \$1,235.28
No. of securities held after change	
David Foster	6,146,829 fully paid ordinary shares 4,000,000 options exercisable at \$0.15 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months)
Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	126,328 fully paid ordinary shares
Citicorp Nominees Pty Limited	71,303 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	i) Exercise of options ii) Exercise of options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.